... a focused investment in Life Sciencewww.onelifefund.li

ISIN: LI0269512732BB: ONELIFU LE

© 2017 Onelife 2

DisclaimerOnelife Fund presentation has been produced by Onelife SA (Onelife). Although utmost care has been exercised in the drafting of this presentation, Onelife, IFOS andVP Bank Group assume no liability for the information contained herein. This presentation needs to be read in conjunction with the current (full and simplified)prospectus as these documents are solely relevant. It is therefore necessary to carefully and thoroughly read the current prospectus before investing in this fund.Subscription of shares will only be accepted on the basis of the current (full and simplified) prospectus.The current (full and simplified) prospectus as well as annual report may be obtained free of charge at Verwaltungs- und Privat-Bank Aktiengesellschaft, Aeulestrasse 6,LI-9490 Vaduz and IFOS Internationale Fonds Service Aktiengesellschaft, Aeulestrasse 6, LI-9490 Vaduz. Up-to-date information can be accessed at any time on thewebsites of VP Bank at www.vpbank.com, IFOS Internationale Fonds Service Aktiengesellschaft at www.ifos.li and the Liechtenstein Investment Fund Association atwww.lafv.li.The details in this presentation are given for information purposes only and do not constitute an offer or a promotion that invites to purchase shares in this fund. Also,this presentation does not constitute investment advice and pays no regard to the specific or future investment objectives, financial or tax situation or particular needs ofany specific recipient. The value and the returns achieved on the fund mentioned in this presentation may rise or fall. It is possible that an investor will not recover theamount that he originally invested. Also, past performance is not a reliable indicator of future results and the performance shown does not take into account anycommissions and costs charged when subscribing and redeeming units.This presentation might contain forward-looking statements, including, but not limited to, statements relating to future market developments. While these forward-lookingstatements represent our carefully researched judgments and expectations, uncertainties and various risk factors could cause actual developments and results to differmaterially from our statements.This fund is domiciled in the Principality of Liechtenstein. Due to different registration proceedings, no guarantee can be given that the fund and – if applicable – sub-funds are or will be registered in every jurisdiction and at the same time. Please note, that in any country where a fund is not registered for public offering, they may,subject to applicable local regulation, only be distributed in the course of ‘private placements’ or institutional investments. Shares in funds are not offered for sale incountries where such sale is prohibited by law.This fund is not registered under the United States Securities Act of 1933. Fund units must therefore not be offered or sold in the United States neither for or on accountof US persons (in the context of the definitions for the purposes of US federal laws on securities, goods and taxes, including Regulation S in relation to the United StatesSecurities Act of 1933). Subsequent unit transfers in the United States and/or to US persons are not permitted. Any documents related to this fund must not becirculated in the United States.

© 2017 Onelife

Ongoing projects• Initiator of Onelife Fund• Private Equity vehicle (Onelife AG) • Consulting to Hedge Funds• Advisory to financial institutions, banks and

family offices• Collaboration with non-profit organizations • M&A and In/out licensing project acquisitions• Free Advisory services to Life Science

research companies (Bench2Bed)• Assets acquisition scouting• Participation to new company start-up

(Senexta Therapeutics SA, Wazzamba SA)

33

Onelife SA: a new approach to advisoryONELIFE is a Swiss advisory company with strong expertise in pharmaceuticaland biotech. ONELIFE uses a virtual network of highly experienced consultantsapplying ethical considerations and commitment.

Member of:The number one cluster for Biotech in Switzerland.

The Swiss Association of private equity, venture capital and corporate finance industries.

United Nation initiative for Responsible Investment.

The leading financing platform for Swiss high-tech start-up's.

© 2017 Onelife 4

Our key teamEnrico Braglia, M.Sc (Economics), ONELIFE founder and CEO received a degree from the Commercial UniversityBocconi in Milan (Italy). He joined the Swiss pharmaceutical group Helsinn in 1991, from a previous tenure with FininvestFinancial Services, formerly a Mediaset company, where he was responsible for the International Treasury and FinanceOffice. In Helsinn, he served as Co-CEO and was responsible for all operations including the manufacturing, R&D,regulatory and finance. In 2006 he founded ONELIFE as a strategic and investment company. He is involved in severalprofessional and no profit International organizations and board member in many innovative companies.

Federica Pericle, PhD, MBA has solid experience with large Biotech European Funds, VCs and several biotechnologycompanies in Europe and the U.S. Previously Dr. Pericle was the Director of the Oncology Program at Valentis. She hasalso worked as Senior Scientist at the National Cancer Institute. Dr. Pericle has 15 years of research experience in thefields of cancer gene therapy and cancer immunotherapy. She has led the research of 10 product candidates for thetreatment of cancer and has published over 40 scientific articles in peer-review journals. Dr. Pericle received her Ph.D. inBiological Sciences from Turin University and has a specialization in Immunology/Cancer Immunotherapy from theUniversity of South Florida and also holds an MBA from Texas A&M University.

Massimo Colnago, M.Sc (Economics) ONELIFE Equity Analyst, received a degree from the Bocconi University (Italy).After an experience in Zurich Capital Markets London where he participated in the launch of hedge fund indices, portfolioanalysis and risk scoring; in 2002 he joined Money Bonds Investments SA in Lugano (Switzerland), a wealth managementfirm, as an Equity Trader. He then became a director for two hedge funds. He is a Certified Financial Fiduciary since June2007 and also a member of OAD-FCT. In March 2008 he joined Unifida Finance SA as a Wealth Manager and EquityTrader.

© 2017 Onelife

What is Life Science?

5

Healthcare

Healthcare Equipment &

Services

Pharmaceuticals, Biotechnology & Life Science

Healthcare: The act of taking preventative ornecessary medical procedures to improve aperson's well-being.

Pharmaceutical: The industry discovers,develops, produces, and markets drugs for useas medications.

Biotechnology: the manipulation of livingorganisms or their components to producecommercial products.

Life Sciences: include companies in the fields ofbiotechnology, pharmaceuticals, biomedicaltechnologies, life systems technologies,nutraceuticals, cosmeceuticals, food processing,environmental, biomedical devices…

© 2017 Onelife 6

Source: US Census, Bloomberg, DESA, WHO, American Alzheimer’s Society

The Facts:

•The world’s population is living longer•Half of the world’s diseases has no cure•Need for new drugs (only 22 new in 2016)•Life Science market growth +8%(y/y)•High number of companies (>3’000)•Great earning potential•M&A and news-flow drive the market

Age

Why invest in Life Science?

Alzheimer’s Disease (AD)

•Over 47 million worldwide have dementia•By 2030 over 76 million affected by AD•2nd most feared disease•A case of AD is diagnosed every 66 seconds in US•1 in 3 seniors dies with AD•> $ 240 billion the AD costs in US

© 2017 Onelife

Complexity of the Life Science sector

7

• >1.5 b$ are the cost of a new drug• 12 years is the average time to reach the market •

© 2017 Onelife

Why Onelife to invest in Life Science?

8

Helpful Harmful

Inte

rnal

Strengths• 70 years of combined experience• Entrepreneurial approach• Long term view• Stability of the team• 10 years track record• Direct presence in USA

Weaknesses• Conservative approach• Long term view• ...

Exte

rnal

Opportunities• The world’s population is living longer• Life Science market growth +8%(y/y)• High number of companies (>3’000)• Need for new drugs (22 new in 2016)• Great earning potential• M&A and news-flow drive the market

Threats• Government pressure on pricing• Legal cases in the US• US and EU election consequence• High volatility• Long development cycle, over 15 years

© 2017 Onelife 9

Where we invest in Life Science

Years

Size

ResearchTarget

Discovery Lead

First Selection

Preclinical Safety

IND Phase

Clinical Phase I

Clinical Phase II

Clinical Phase III

Registration Phase

Launch Phase

CROs Services

Laboratory Services

Toxicology Services

Health Services

Distribution

Legal & Patent

Chemical

Software

Delivery Systems

Devices

Nursing Homes

The Fund invests in a global, diversified equity portfolio only in life science

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Legend/size

R&D (500-1b$)

PH1 (1-10 b$)

PH (>10 b$)

VorführenderPräsentationsnotizenDefinitions:IND Phase – Clinical Phases:I - II - III - Registration -

© 2017 Onelife

How Onelife invests in Life Science

1010

Sale

St

rate

gyFull Analysis20-30Equities

QuantitativeAnalysis

Scouting• Deep market monitoring • Searching for opportunities• Top level networking• Opinion leader support • Conferences • Management interviews

Review &

Follow-upQualitativeAnalysis

Database>200

Equities

• Hands-on experience in every stage of the development and the commercial rollout• Unique combination of Industry Expertise and Financial Know-How• Direct presence in USA

(*) The Database is sorted by company size, group (i.e. R&D), country, therapeutic area

© 2017 Onelife

More on our proprietary model

11

Each company has a qualitative and quantitative score. All companies that pass the initial scrutiny, enter the databasesystem. A full valuation, based on a risk analysis system, is carried on to objectively assess the investment. Analysis isperformed by segment or category (PH, PH1, R&D).

© 2017 Onelife 12

0

150

1

80

250

Qua

litat

ive

Quantitative0 50 100 150

NOVN

GILD

MYGN

ENDP

ABBV

An Example of asset allocation (not our actual portfolio)

Not generated by a Computer but directly inputted by hand by Onelife Team.Identification and selection of “Investment Zone” companies (in Orange)Follow-up on companies in the “Monitoring Zone”(blu)

Legend

R&D (500-1b$)

PH1 (1-10 b$)

PH (>10 b$)

© 2017 Onelife

Example: Go & No Go decisions

+121%

+240%

17 Oct 2012, MannKind raises more capital creating abuying opportunity, Onelife builds its position

11 Apr 2013, Onelife sells half of the position for a profitof +121%

13 may 2013, rumors of acquisition fuel a further rise instock price and Onelife sells the remaining half for a profitof +240%

27 Jun 2014, FDA grants approval to MannKind’sAfrezza, Onelife decided to not invest.

11 Aug 2014, Mannkind signs a commercial partnershipwith Sanofi. Onelife did not invest.

05 jan 2016, Sanofi returns the rights of Afrezza toMannKind following unsuccessful marketing

MannKind developed an inhalable insulin called Afrezza. FDA twice rejected the registration due to lack of data.Final clinical data were published in 2013 and NDA was granted in June 2013.

-80%

Conservative approach: Partial sell-off to assure investment security.

Industry expertise:knowing the lifecycle and commercial drug potential

13

© 2017 Onelife

• Life Science sector UCITS V fund, • Open-end unlimited duration• Medium, long risk profile• Daily NAV in USD without hedging• 1’000 USD minimum investment• 1.18% All in fee without performance fee• Tax transparent and distribution in FL, CH, D, A

14

The Onelife Fund

© 2017 Onelife

Track record and experience(not back testing)

15

• PSF better in downturn and in positive cycle• Over 80% return in 7 years

• Over 93 mio USD AUM• Volatility 10.87 - Beta 0.28

MSCI World IndexProspera Senectute Fund Sicav-SIF

1 year delay

Source: Bloomberg

© 2017 Onelife

2017 and beyond…

16

• Global uncertainty and the high volatility scares the investor • Science driven decision instead of fundamentals• Long development cycle, over 12 years• New US president, EU elections• Government pressure on pricing / reimbursement

BUT• Innovation is high meaning IP protection, higher prices and less competition• Pressure on drug price slow down after Trump election• Over 400 events in 2017, possibly 50 approvals of new drugs• Market growth steadily in the next 5 years (>5 % Y/Y)• Company valuations are attractive• Dividend are over 3.5% in many big life science company• M&A are opportunities for exceptional performance

© 2017 Onelife 17

Why Onelife Fund?• Focus only in the Life Science Sector• Hands-on experience in every stage of the development and the

commercial rollout• Unique combination of Industry Expertise and Financial Know-How• Direct presence in USA• Team is privately invested in the fund • Proven success: 10 years of track records and over 80% return

VorführenderPräsentationsnotizenYear by year grow .8.7% CAGR

© 2017 Onelife 18

Fund structure & Contact

AuditorsPWC

Risk ManagementVP Fund Solution

CustodyVP Bank

AdministrationVP Fund Solution

Initiator & AdvisorOnelife SAVia Cantonale 16900 Lugano - Switzerland

Phone: +41 91 924 24 00E-mail: info@onelife.chWeb: www.onelife.ch

Marketing & IR AC Innovation GmbH Am Königsberg 10 82211 Herrsching am Ammersee Germany

Phone: + 49 170 7345 775 E-mail: usp@acinnovation.com

Investor ManagersAlean (Capital) AGNeugasse 15FL-9490 Vaduz, Liechtenstein

Phone: +423 384 01 53E-mail: info@aleancapital.com

mailto:info@onelife.chmailto:usp@acinnovation.commailto:info@aleancapital.com

Foliennummer 1DisclaimerOngoing projectsOur key teamWhat is Life Science? Foliennummer 6Complexity of the Life Science sectorWhy Onelife to invest in Life Science?Where we invest in Life ScienceHow Onelife invests in Life ScienceMore on our proprietary modelAn Example of asset allocation (not our actual portfolio)Example: Go & No Go decisionsThe Onelife Fund Track record and experience�(not back testing)2017 and beyond…Why Onelife Fund? Fund structure & Contact